Fulcrum Therapeutics announced that its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo. In addition, secondary endpoints did not achieve nominal statistical significance. The safety and tolerability profile of losmapimod was consistent with previously reported studies. In light of these results, Fulcrum plans to suspend the losmapimod program in FSHD. Fulcrum had approximately $273.8M in cash, cash equivalents, and marketable securities as of June 30, 2024. Fulcrum intends to use these resources to advance pociredir for the treatment of SCD, novel therapeutic agents for the treatment of Diamond-Blackfan Anemia, and early discovery programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
- Fulcrum Therapeutics upgraded to Neutral at BofA on FSHD study success chance
- Fulcrum Therapeutics upgraded to Neutral from Underperform at BofA
- Fulcrum Therapeutics price target raised to $15 from $14 at RBC Capital
- Biotech Alert: Searches spiking for these stocks today